NDAORALCAPSULE
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
7
Data completeness
5/8 — Partial
ACCRUFER (ferric maltol) by Shield Therapeutics is 12. First approved in 2019.
Drug data last refreshed 15h ago · AI intelligence enriched 18h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACCRUFER (ferric maltol) is an oral iron replacement therapy approved in 2019 for iron deficiency with or without anemia. It delivers iron via a novel maltol complex that dissociates in the gastrointestinal tract, allowing efficient absorption across the intestinal wall and transfer to transferrin and ferritin. The drug is indicated for adults and pediatric patients 10 years and older with iron deficiency.
Peak9.1 years to LOE
Product is at peak commercial maturity with 9.1 years of patent protection remaining; brand team remains active though limited linked job visibility suggests modest commercial footprint.
Mechanism of Action
12.1 Mechanism of Action ACCRUFER delivers iron for uptake across the intestinal wall and transfer to transferrin and ferritin. 12.2 Pharmacodynamics ACCRUFER has been shown to increase serum iron parameters, including ferritin and transferrin saturation (TSAT) in adults and pediatric patients 10…
Worked on ACCRUFER at Shield Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.